ALSO NOTED: Amgen selects manufacturing site; Discovery Labs inks collaboration deal;and much more...

> Amgen has reportedly selected a site in Ireland for a $1.54 billion manufacturing plant. Release

> Discovery Labs and Chrysalis Technologies are partnering to develop and commercialize aerosolized surfactant replacement therapies for treating respiratory conditions. Article

> Alexion Pharmaceuticals has announced three year cumulative data for patients given eculizumab. Release

> TransGene has released positive Phase I/II data for an experimental therapy for skin cancer. Release

> Ambit Biosciences has expanded its collaboration with Bristol-Myers Squibb. Release

> Vanda Pharmaceuticals has initiated a Phase III clinical study of iloperidone, an antipsychotic agent in development for schizophrenia and related disorders. Release

> Amgen, Supergen and MGI Pharma all used the weekend meeting of the American Society of Hematology to tout their clinical trial data for experimental therapies. Article

> Germany's Schering AG says it will lay off between 65 and 125 workers at its Jenapharm unit as part of a cost-cutting program. Jenapharm's research activities will be integrated into Schering's Berlin operations. Report

> In a Phase II study of patients with advanced indolent non-Hodgkin's lymphoma who were previously exposed to multiple courses of therapy, 74 percent responded to Cephalon's Trenda (bendamustine HCl), including 35 percent with a complete response. Release

And Finally… Health officials are warning that a rapid HIV test is delivering too many false positives. Article